ClinicalTrials.gg
CompletedNCT01683253REIN-PDUpdated Mar 10, 2021

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

A Phase 4 interventional study of Levodopa/Carbidopa(200mg/50mg) and Dopaminergic Agonists in Impulse Control Disorder, sponsored by Sandoz. Completed at 5 sites in Korea, Republic of. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Sandoz (formerly part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist to levodopa/carbidopa in patients with Parkinson's disease who have been treated with dopaminergic medications.

Read the detailed description
  • PRIMARY OBJECTIVE To evaluate the improvement of mMIDI(modified version of Minnesota Impulsive Disorders Interview,Korean version) score from the baseline to 12 weeks or LOCF(Last Observation Carried Forward)
  • SECONDARY OBJECTIVE i) To evaluate the improvement of neuropsychiatric profiles from the baseline to 12 weeks or LOCF ii) To evaluate the improvement of UPDRS(Unified Parkinson's Disease Rating Scale)Score from the baseline to 12 weeks or LOCF
02

Conditions studied

  • Impulse Control Disorder
03

In context

Disruptive, Impulse Control, and Conduct Disorders

56 studies on the registry are indexed under Disruptive, Impulse Control, and Conduct Disorders; 17 are open to participants now.

This study's enrollment of 150 is above the median of 48 across 46 interventional studies indexed under Disruptive, Impulse Control, and Conduct Disorders.

Browse Disruptive, Impulse Control, and Conduct Disorders studies →

Lead sponsor

Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

First submitted before Sandoz left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a diagnosis of idiopathic PD according to United Kingdom Parkinson's Disease Brain Bank Criteria
  • mMIDI ≥ 3 score with ICD
  • Patients must be on an anti-parkinson treatment at least 6 months before screening.
  • for this protocol, dopamine agonists should be included in his/her anti-parkinson treatment.
  • 30years ≤ patients \< 80years of age, male or female
  • patients must give written before any assessment is performed

Exclusion criteria

Exclusion Criteria:

  • Requirement of treatment with serious cognitive disorder, behavioral disorder, or mental illness currently or in the future
  • for the patients ≤ 65years: K-(korean version of Mini-Mental State Exam) ≤24, or for the patients ≥ 66years: K-MMSE ≤ 20, or the patients have dementia(incl. early dementia) even though K-MMSE score is more than 20
  • Requirement of treatment more than 6times per day due to the severe motor fluctuation.
  • Severe dyskinesia
  • DBS(Deep Brain Stimulation)or any other surgical treatment
  • History of melanoma or not-diagnostic skin trouble/skin lesions
  • narrow angle glaucoma
  • clinically serious surgical or medical condition
  • malignant tumor
  • use of other drugs at the time of enrollment within 4weeks
  • pregnant, nursing or lactating women
  • women of
  • history of or allergy to levodopa/carbidopa
  • any serious disease according to the investigator's discretion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Levodopa/Carbidopa(200mg/50mg)

    Drug: Levodopa/Carbidopa(200mg/50mg)

  • Experimental
    Control A (dopaminergic agonist )

    Parkinson patients treated with anti-Parkinson drug over 6 months.

    Drug: Dopaminergic Agonists

  • No intervention
    Control B (no drug)

    Parkinson diseased patients not treated.

Interventions

06

What researchers measure

Primary outcomes

  1. mMIDI(modified Minnesota Impulsive Disorders Interview)

    To evaluate the improvement of mMIDI(Korean version) score from the baseline to 12 weeks or LOCF(Last Observation Carried Forward)

    Time frame: 12weeks

Secondary outcomes

  1. Neuropsychiatric profile

    To evaluate the improvement of neuropsychiatric profiles from the baseline to 12 weeks or LOCF \* Neuropsychological assessment * General cognitive status: K-Minimental status exam(K-MMSE) * Psychiatric profile: * Neuropsychiatric inventory (K-NPI) * Beck depression inventory (BDI) * Barratt impulsiveness scale (BIS) * Beck anxiety inventory (BAI) * State-trait anger expression inventory (STAXI) * Obsessive compulsive inventory (OCI) * Evaluation of global change: * Patient global impression of improvement (PGI-I) * Clinical global impression of improvement (CGI-I)

    Time frame: 12 weeks

07

Study locations

5 sites
  • Sandoz Investigative Site
    Anyang, Korea, Republic of
  • Sandoz Investigative Site
    Daegu, Korea, Republic of
  • Sandoz Investigative Site
    Pusan, Korea, Republic of
  • Sandoz Investigative Site
    Seongnam, Korea, Republic of
  • Sandoz Investigative Site
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Lee JY, Jeon B, Koh SB, Yoon WT, Lee HW, Kwon OD, Kim JW, Kim JM, Ma HI, Kim HT, Baik JS, Cho J; (REIN-PD Investigators). Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):30-37. doi: 10.1136/jnnp-2018-318942. Epub 2018 Oct 25. PubMed 30361296 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 11, 2012
Start
Nov 2012
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01683253
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Sep 11, 2012
Start date
Nov 2012
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Mar 10, 2021

Study contacts

Jinwhan Cho, MD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa · Dopamine agonists

Start the discussion